Home > Dosing
Available strengths of JAKAVI tablet
Reference
-
JAKAVI® (ruxolitinib) tablets: EU Summary of Product Characteristics. Novartis; January 2022.
It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.
JAKAVI® (ruxolitinib) tablets: EU Summary of Product Characteristics. Novartis; January 2022.
This is an international site for JAKAVI® (ruxolitinib) and is intended for Healthcare Professionals outside the United States. Are you a non-US resident?
The information on the site is not country-specific, and may contain information that is outside the approved indication in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country. Please contact your local representative for local prescribing information via www.novartisoncology.com/contactus.
IMPORTANT: The product information on this website is based on the European Summary of Product Characteristics (EUSmPC).